GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD

Who can take part

Inclusion Criteria: * Age 40-80 years * Diagnosis of chronic obstructive pulmonary disease (COPD) with post-bronchodilator FEV₁/FVC \< 0.70 * GOLD stage 1-3 COPD (FEV₁ \>30% predicted) * Former smoker with a smoking history of at least 10 pack-years * Body mass index (BMI) ≥27 kg/m² with at least one weight-related comorbidity (e.g., prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) or BMI 30-40 kg/m² * Able and willing to provide written informed consent * Able to comply with study procedures and follow-up visits Exclusion Criteria: * Type 2 diabetes mellitus (HbA1c \> 6.5%) * Pregnancy or breastfeeding * Coagulopathy, defined as INR \> 1.4 or platelet count \<80,000/μL * Active malignancy, including lung cancer * Use of medications known to significantly alter muscle protein metabolism within 6 weeks of enrollment (e.g., oral corticosteroids, tamoxifen, high-dose estrogen, testosterone) * Personal or family history of medullary thyroid carcinoma * Multiple endocrine neoplasia syndrome type 2 (MEN2) * Known hypersensitivity or contraindication to tirzepatide or its components * History of pancreatitis * Severe gastrointestinal disease that, in the opinion of the investigator, would increase risk from study participation * Significant diabetic retinopathy * Clinically significant renal impairment * Clinically significant gallbladder disease * Current treatment with a DPP-4 inhibitor * COPD exacerbation within 60 days prior to enrollment * Participation in pulmonary rehabilitation within 2 weeks prior to enrollment * Any medical, psychiatric, or social condition that, in the opinion of the investigators, may interfere with study participation, adherence to study procedures, or participant safety

Registry changes

No changes recorded since the trial was added.